Hyaluronic Acid Viscosupplementation - Market Insights, Competitive Landscape, and Market Forecast - 2030

The Hyaluronic Acid Viscosupplementation Market By Treatment Type (Single Injection, Three Injections, And Five Injections), By End-User (Hospitals, Specialty Clinics, And Others), And By Geography Is Expected To Grow At A Steady CAGR forecast till 2030 owing to the increasing prevalence of osteoarthritis, particularly among the geriatric population and increasing demand for non-surgical treatment options for osteoarthritis

The global hyaluronic acid viscosupplementation market was valued at USD 3,872 million in 2023, growing at a CAGR of 7.29% during the forecast period from 2024 to 2030 to reach USD 5,900 million by 2030. The hyaluronic acid viscosupplementation market is observing optimistic market growth due to the rising prevalence of osteoarthritis across the globe. Further, the rise in the geriatric population, increasing demand for minimally invasive treatment options for osteoarthritis, favorable reimbursement policies, and growing focus on improving the safety, efficacy, and affordability of hyaluronic acid viscosupplementation for patients are expected to result in the appreciable revenue growth in the hyaluronic acid viscosupplementation market during the forecast period (2024-2030).

Hyaluronic Acid Viscosupplementation Market Dynamics:

According to the World Health Organization 2022, worldwide around 528 million people were suffering from osteoarthritis in 2019. As per the same source osteoarthritis contributed to 19 million years lived with disability (YLDs). Osteoarthritis also known as "wear and tear" disease is associated with symptoms such as extreme pain, swelling, and others caused by the wearing down of cartilage within the joints. Hyaluronic acid viscosupplementation injections are given to patients suffering from osteoarthritis to reduce their pain and swelling, thereby providing relief to the patients.

The increasing geriatric population is another factor accelerating the market for hyaluronic viscosupplementation market. For instance, according to WHO 2022, it has been expected that, globally by 2030, out of 6 at least 1 person will have his/her age 60 years or above. As per the same source, by 2050, the number of people aged 60 years or above will reach around 2.1 billion. The fact mentioned by the American College of Rheumatology 2022, says that osteoarthritis commonly occurs in the old age population and people aged 40 or above are most likely to suffer from it.

The growing preference for minimally invasive and non-surgical treatment options for osteoarthritis is further going to enhance the growth of the hyaluronic acid viscosupplementation market. As a non-surgical alternative, hyaluronic acid viscosupplementation injections are found to be more effective in relieving pain due to osteoarthritis and are crucial for delaying complicated orthopedic surgical procedures such as knee replacement and others.

However, the stringent regulatory approval process for hyaluronic acid viscosupplementation and the presence of other treatment options for osteoarthritis may act as a restraint in the growth of the hyaluronic acid viscosupplementation market.

The hyaluronic acid viscosupplementation market was negatively impacted during the period of the COVID-19 pandemic owing to lockdown impositions as a measure to prevent the spread of COVID-19 infection among hospital personnel and the general public. Due to shifted focus on first treating patients with COVID-19 infection, the orthopedic and other departments were closed down in hospitals and clinics, leading to a halt in the diagnosis and treatment of arthritic patients. Also, the manufacturing, supply, distribution, import, export, and other related activities of the hyaluronic acid viscosupplementation market was severely hampered, thereby negatively impacting the growth of the hyaluronic acid viscosupplementation market. Nevertheless, the hyaluronic acid viscosupplementation market is in a recovery phase owing to the resumption of activities across all the sectors including healthcare and pharmaceutical, thereby providing ample opportunities for the hyaluronic acid viscosupplementation market to grow at significant revenue during the forecast period.

Hyaluronic Acid Viscosupplementation Market Segment Analysis:

Hyaluronic Acid Viscosupplementation Market by Treatment Type (Single Injection, Three Injections, and Five Injections), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the treatment type of the Hyaluronic Acid Viscosupplementation Market, the three injections category is expected to amass significant revenue share in the year 2023.

In the case of the three injections category, the hyaluronic acid viscosupplementation injections having hyaluronic acid in small amounts are administered to patients suffering from osteoarthritis for three weeks, once per week.

Post administration of injections, patients may witness a reduction in pain and inflammation, improvement in the movement of joints, and slowing down of the progression of osteoarthritis, usually from the fourth week onwards.

For example, VISCO-3(TM) Sodium Hyaluronate by Zimmer Biomet offers a non-surgical treatment for patients with knee pain due to osteoarthritis. In this, the patient will receive a 2.5 mL injection of VISCO-3 Sodium Hyaluronate once a week for 3 weeks (a total of 3 injections). In clinical studies for VISCO-3(TM) Sodium Hyaluronate, it was demonstrated that patients treated with VISCO-3 Sodium Hyaluronate had a 52% reduction in their pain at week 12 and it is safe and effective for knee osteoarthritis.

Therefore, owing to the above-mentioned factors, the three injection category is expected to generate considerable revenue thereby pushing the overall growth of the global hyaluronic acid viscosupplementation market during the forecast period.

North America is expected to dominate the overall Hyaluronic Acid Viscosupplementation Market:

Among all the regions, North America is estimated to account for the largest share of the hyaluronic acid viscosupplementation market in the year 2023. Owing to the significance of key growth factors such as the rising prevalence of osteoarthritis, the growing burden of the old age population, sophisticated healthcare infrastructure, the presence of key players in the market, and fast regulatory approval for new products, in the region, the market for hyaluronic acid viscosupplementation is expected to grow during the forecast period 2024-2030.

The increasing patient population suffering from osteoarthritis is the key factor accelerating the growth of the hyaluronic acid viscosupplementation market. The data published by CDC 2020 states that approximately 32.5 million US adults are suffering from osteoarthritis.

The growing burden of the geriatric population is further going to increase the demand for hyaluronic acid viscosupplementation in the region. According to the data provided by the World Bank 2022, about 17% of US citizens aged 65 and above in 2022. Also, according to CDC 2022, around 54.1 million US adults were aged 65 or older in 2019. As per the same source, it has been estimated that by 2060, this number will reach up to 94.7 million in the US. As per the Arthritis by the Numbers report published by the Arthritis Foundation 2019, the risk for knee osteoarthritis increases with age and the annual incidence of knee OA is highest between 55 and 64 years old.

Hence, the above-mentioned factors are going to increase the growth of the hyaluronic acid viscosupplementation market in the region.

Hyaluronic Acid Viscosupplementation Market Key Players:

Some of the key players operating in the hyaluronic acid viscosupplementation market include Teva Pharmaceutical Industries Ltd., Anika Therapeutics, Inc., APTISSEN, Sanofi, AVNS, Bioventus, Fidia Farmaceutici S.p.A., Miravo Healthcare(TM), Zimmer Biomet, Johnson & Johnson Services, Inc., and others.

Recent Developmental Activities in the Hyaluronic Acid Viscosupplementation Market:

In December 2022, Avanos Medical, Inc., announced that it has entered into a definitive agreement to acquire OrthogenRx, Inc., an emerging leader in viscosupplementation therapies for the treatment of knee osteoarthritis (OA) pain, for a total consideration of USD 160 million.

Key Takeaways from the Hyaluronic Acid Viscosupplementation Market Report Study

Market size analysis for current hyaluronic acid viscosupplementation market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the hyaluronic acid viscosupplementation market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global hyaluronic acid viscosupplementation market.

Various opportunities available for the other competitor in the hyaluronic acid viscosupplementation market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current hyaluronic acid viscosupplementation market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for hyaluronic acid viscosupplementation market growth in the coming future?

Target Audience who can be benefited from this Hyaluronic Acid Viscosupplementation Market Report Study

Hyaluronic acid viscosupplementation products providers

Research organizations and consulting companies

Hyaluronic acid viscosupplementation- related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in Hyaluronic acid viscosupplementation

Various End-users who want to know more about the hyaluronic acid viscosupplementation market and the latest innovations and developments in the hyaluronic acid viscosupplementation market.

Frequently Asked Questions for the Hyaluronic Acid Viscosupplementation Market:

1. What is hyaluronic acid viscosupplementation?

Hyaluronic acid viscosupplementation is a non-surgical treatment option for osteoarthritis in which a gel-like fluid called hyaluronic acid is administered directly into the knee joint which then acts as a lubricant and allows the bones to move smoothly over each other and also acts as a shock absorber for joint loads.

2. What is the market for global hyaluronic acid viscosupplementation?

The global hyaluronic acid viscosupplementation market was valued at USD 3,872 million in 2023, growing at a CAGR of 7.29% during the forecast period from 2024 to 2030 to reach USD 5,900 million by 2030.

3. What are the drivers for the global hyaluronic acid viscosupplementation market?

The growth of the hyaluronic acid viscosupplementation market is primarily being boosted by the increasing prevalence of osteoarthritis, particularly among the old age population. Further, the increasing importance of hyaluronic acid viscosupplementation as a minimally invasive treatment option for osteoarthritis, and a surge in product development activities are contributing to the overall growth of the hyaluronic acid viscosupplementation market during the forecast period from 2024-2030.

4. Who are the key players operating in the global hyaluronic acid viscosupplementation market?

Some of the key players operating in the hyaluronic acid viscosupplementation market include Teva Pharmaceutical Industries Ltd., Anika Therapeutics, Inc., APTISSEN, Sanofi, AVNS, Bioventus, Fidia Farmaceutici S.p.A., Miravo Healthcare(TM), Zimmer Biomet, Johnson & Johnson Services, Inc., and others.

5. Which region has the highest share in the hyaluronic acid viscosupplementation market?

North America is expected to dominate the overall hyaluronic acid viscosupplementation market during the forecast period from 2024-2030. The factors such as the increasing patient population suffering from osteoarthritis, the growing burden of the geriatric population, sophisticated healthcare infrastructure, regulatory approval for new products, and high awareness are driving the growth of the hyaluronic acid viscosupplementation market in the region.